Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Dec;43(12):1956-1969.
doi: 10.1002/humu.24454. Epub 2022 Sep 6.

Mosaicism in tuberous sclerosis complex: Lowering the threshold for clinical reporting

Affiliations

Mosaicism in tuberous sclerosis complex: Lowering the threshold for clinical reporting

Zimeng Ye et al. Hum Mutat. 2022 Dec.

Abstract

Tuberous sclerosis complex (TSC) is a multi-system genetic disorder. Most patients have germline mutations in TSC1 or TSC2 but, 10%-15% patients do not have TSC1/TSC2 mutations detected on routine clinical genetic testing. We investigated the contribution of low-level mosaic TSC1/TSC2 mutations in unsolved sporadic patients and families with TSC. Thirty-one sporadic TSC patients negative on routine testing and eight families with suspected parental mosaicism were sequenced using deep panel sequencing followed by droplet digital polymerase chain reaction. Pathogenic variants were found in 22/31 (71%) unsolved sporadic patients, 16 were mosaic (median variant allele fraction [VAF] 6.8% in blood) and 6 had missed germline mutations. Parental mosaicism was detected in 5/8 families (median VAF 1% in blood). Clinical testing laboratories typically only report pathogenic variants with allele fractions above 10%. Our findings highlight the critical need to change laboratory practice by implementing higher sensitivity assays to improve diagnostic yield, inform patient management and guide reproductive counseling.

Keywords: high-depth sequencing; mosaic mutations; parental mosaicism; tuberous sclerosis complex.

PubMed Disclaimer

References

REFERENCES

    1. Au, K. S., Williams, A. T., Gambello, M. J., & Northrup, H. (2004). Molecular genetic basis of tuberous sclerosis complex: From bench to bedside. Journal of Child Neurology (St. Louis, MO), 19(9), 699-709. https://doi.org/10.1177/08830738040190091101
    1. Au, K. S., Williams, A. T., Roach, E. S., Batchelor, L., Sparagana, S. P., Delgado, M. R., Wheless, J. W., Baumgartner, J. E., Roa, B. B., Wilson, C. M., Smith-Knuppel, T. K., Cheung, M. Y., Whittemore, V. H., King, T. M., & Northrup, H. (2007). Genotype/phenotype correlation in 325 individuals referred for a diagnosis of tuberous sclerosis complex in the United States. Genetics in Medicine, 9(2), 88-100. https://doi.org/10.1097/gim.0b013e31803068c7
    1. Batalini, F., Peacock, E. G., Stobie, L., Robertson, A., Garber, J., Weitzel, J. N., & Tung, N. M. (2019). Li-Fraumeni syndrome: Not a straightforward diagnosis anymore-the interpretation of pathogenic variants of low allele frequency and the differences between germline PVs, mosaicism, and clonal hematopoiesis. Breast Cancer Research, 21(1), 107. https://doi.org/10.1186/s13058-019-1193-1
    1. Baybis, M., Yu, J., Lee, A., Golden, J. A., Weiner, H., McKhann, G., 2nd, Aronica, E., & Crino, P. B. (2004). mTOR cascade activation distinguishes tubers from focal cortical dysplasia. Annals of Neurology, 56(4), 478-487. https://doi.org/10.1002/ana.20211
    1. Caban, C., Khan, N., Hasbani, D. M., & Crino, P. B. (2017). Genetics of tuberous sclerosis complex: Implications for clinical practice. The Application of Clinical Genetics, 10, 1-8. https://doi.org/10.2147/TACG.S90262

Publication types

MeSH terms

Substances

LinkOut - more resources